Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

Area of Science:

• Pharmacokinetics and drug development
• Immunology and autoimmune diseases
• Computational modeling in medicine

Background:

• Ritlecitinib, an oral Janus kinase 3 inhibitor, is in clinical development for alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis.
• Simultaneous clinical trial readouts necessitate strategic planning for population pharmacokinetic (PopPK) model development.

Purpose of the Study:

• To develop and evaluate a robust PopPK model for ritlecitinib.
• To ensure timely decision-making throughout the drug's clinical development lifecycle.
• To address clinical questions regarding systemic exposure of ritlecitinib.

Main Methods:

• Utilized data from 12 clinical trials (Phase I, II, and III) involving healthy participants and patients with autoimmune conditions.
• Employed a stepwise PopPK modeling approach with three iterative updates, leveraging accumulating data.
• The final model was a two-compartment model with non-stationary clearance and bioavailability influenced by peripheral compartment concentrations.

Main Results:

• Three iterations of the ritlecitinib PopPK model were successfully developed, supporting study readouts for alopecia areata, vitiligo, and ulcerative colitis.
• The modeling process evolved from initial structural modeling to comprehensive covariate testing and evaluation.
• The final model accurately described ritlecitinib pharmacokinetics and informed clinical development decisions.

Conclusions:

• The iterative PopPK modeling approach effectively managed accumulating data throughout ritlecitinib's development.
• This strategy successfully addressed key clinical questions related to systemic exposure.
• The developed model informed the approved product label, demonstrating its utility in drug development.